1,800,440 Shares in ADMA Biologics Inc $ADMA Bought by Vaughan Nelson Investment Management L.P.

Key Points

• Vaughan Nelson Investment Management L.P. acquired 1,800,440 shares of ADMA Biologics Inc, valued at approximately $32.8 million, increasing its stake to 0.75% of the company.
• ADMA Biologics reported a quarterly earnings of $0.15 per share and revenue of $121.98 million, surpassing analysts' expectations.
• Analysts have a consensus rating of "Buy" for ADMA Biologics, with an average price target of $27.67 per share.

Vaughan Nelson Investment Management L.P. bought a new position in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 1,800,440 shares of the biotechnology company's stock, valued at approximately $32,786,000. Vaughan Nelson Investment Management L.P. owned 0.75% of ADMA Biologics at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in ADMA. Nuveen LLC purchased a new position in ADMA Biologics in the first quarter valued at about $93,543,000. Driehaus Capital Management LLC increased its position in shares of ADMA Biologics by 114.9% during the first quarter. Driehaus Capital Management LLC now owns 2,946,570 shares of the biotechnology company's stock worth $58,460,000 after acquiring an additional 1,575,363 shares during the last quarter. Invesco Ltd. increased its position in shares of ADMA Biologics by 13.9% during the first quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company's stock worth $255,279,000 after acquiring an additional 1,570,649 shares during the last quarter. Russell Investments Group Ltd. increased its position in shares of ADMA Biologics by 152.7% during the first quarter. Russell Investments Group Ltd. now owns 1,632,675 shares of the biotechnology company's stock worth $32,392,000 after acquiring an additional 986,666 shares during the last quarter. Finally, MetLife Investment Management LLC increased its position in shares of ADMA Biologics by 714.1% during the first quarter. MetLife Investment Management LLC now owns 1,108,911 shares of the biotechnology company's stock worth $22,001,000 after acquiring an additional 972,699 shares during the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a "buy (b-)" rating on shares of ADMA Biologics in a research report on Saturday, September 27th. One analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $27.67.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $14.66 on Friday. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21. The business has a 50 day moving average of $16.76 and a two-hundred day moving average of $18.75. ADMA Biologics Inc has a 52 week low of $13.50 and a 52 week high of $25.67. The company has a market cap of $3.50 billion, a P/E ratio of 17.05 and a beta of 0.47.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.14 by $0.01. The company had revenue of $121.98 million for the quarter, compared to analysts' expectations of $121.77 million. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The business's revenue for the quarter was up 13.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.13 earnings per share. As a group, analysts anticipate that ADMA Biologics Inc will post 0.51 EPS for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.